DVAX - DYNAVAX TECHNOLOGIES CORP

QQQ $ 617.59 $ 1.57 (0.25 %)

DIA $ 471.47 $ 1.60 (0.34 %)

SPY $ 677.70 $ 1.21 (0.18 %)

TLT $ 91.32 $ -0.24 (-0.26 %)

GLD $ 379.50 $ 0.81 (0.21 %)

Previous Close

$ 10.19

Open

$ 10.24

Bid

$ 10.20 x 400

Ask

$ 10.23 x 186

Day's Range

$ 10.21 - $ 10.28

52 Week Range

$ 9.20 - $ 14.63

Volume

1,242,978

Average Volume

Market Cap

1.19B

Beta (5Y Monthly)

$ 1.14

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	02-20-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-22-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-02-2023	03-31-2023	10-Q
11	02-23-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-05-2022	03-31-2022	10-Q
15	02-28-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-04-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-11-2020	12-31-2019	10-K
24	11-07-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-09-2019	03-31-2019	10-Q
27	02-27-2019	12-31-2018	10-K
28	11-06-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-08-2018	12-31-2017	10-K
32	11-03-2017	09-30-2017	10-Q
33	08-07-2017	06-30-2017	10-Q
34	05-08-2017	03-31-2017	10-Q
35	03-13-2017	12-31-2016	10-K
36	11-07-2016	09-30-2016	10-Q
37	08-08-2016	06-30-2016	10-Q
38	05-09-2016	03-31-2016	10-Q
39	03-08-2016	12-31-2015	10-K
40	11-05-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Dynavax Reports Phase 1/2 Data For Shingle...
10/21/2025 20:23:24

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly prese...

Dynavax Presents Topline Data From Part 1 ...
10/21/2025 20:03:10

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profileNewly prese...

robert-f-kennedy-jr-faces-impeachment-push-from-haley-stevens-over-health-care-chaos-and-rising-costs-enough-is-enough

Robert F. Kennedy Jr. Faces Impeachment Pu...
09/26/2025 04:08:24

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secret...

trump-advises-parents-to-split-vaccines-delay-hepatitis-b-shots-until-age-12-this-is-based-on-what-i-feel

Trump Advises Parents To Split Vaccines, D...
09/23/2025 02:32:30

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain imm...

elizabeth-warren-says-measles-can-hit-record-highs-slams-rfk-jrs-cdc-panel-for-delaying-vaccine-how-does-that-keep-our-kids-safe

Elizabeth Warren Says Measles Can Hit Reco...
09/19/2025 02:14:28

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory pa...

JMP Securities Reiterates Market Outperfor...
08/22/2025 12:48:48

JMP Securities analyst Roy Buchanan reiterates Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and maintains $32...

dynavax-says-investigational-shingles-vaccine-at-par-with-gsks-vaccine-in-early-stage-study

Dynavax Says Investigational Shingles Vacc...
08/21/2025 15:46:22

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in olde...

Dynavax's Shingles Vaccine Candidate Z-101...
08/21/2025 12:11:09

At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerabi...

JMP Securities Maintains Market Outperform...
08/08/2025 15:35:37

JMP Securities analyst Roy Buchanan maintains Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and raises the pri...

Dynavax Technologies Q2 EPS $0.14 Beats $0...
08/07/2025 20:02:02

Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

Dynavax Technologies Comments On A Report ...
06/04/2025 21:07:34

Deep Track Capital Issues Letter To Dynava...
05/15/2025 20:03:06

Cites Evidence That the Company is Not Living Up to Its Potential, As Demonstrated By 26% Year-To-Date Share Price Decline, Und...

Dynavax Defends Strategic Direction, Highl...
05/12/2025 11:36:05

Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director NomineesUrges Stockholders to V...

Breaking Down Dynavax Technologies: 5 Anal...
05/07/2025 21:00:56

JMP Securities Maintains Market Outperform...
05/07/2025 16:40:45

JMP Securities analyst Roy Buchanan maintains Dynavax Technologies (NASDAQ:DVAX) with a Market Outperform and lowers the pri...

vinay-prasads-appointment-to-fdas-cber-triggers-questions-over-future-of-cell-and-gene-therapy-regulation

Vinay Prasad's Appointment To FDA's CBER T...
05/07/2025 13:56:49

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst...

CORRECTION: Dynavax Technologies Q1 Adj. E...
05/06/2025 23:49:36

Dynavax Technologies (NASDAQ:DVAX) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate o...

Earnings Scheduled For May 6, 2025
05/06/2025 08:32:41

Where Dynavax Technologies Stands With Ana...
04/17/2025 20:01:21